WCAMG
EDIT icon

Woodard & Company Asset Management Group’s Editas Medicine EDIT Stock Holding History

Woodard & Company Asset Management Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-150
Closed -$5K – 75
2018
Q3 		$5K Hold
150
– – ﹤0.01% 195
2018
Q2 		$5.38K Hold
150
– – 0.01% 169
2018
Q1 		$5K Hold
150
– – ﹤0.01% 173
2017
Q4 		$5K Buy
+150
New +$3.78K ﹤0.01% 193

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Woodard & Company Asset Management Group's EDIT Position: Q4 2018 in Review

Woodard & Company Asset Management Group sold out of Editas Medicine (EDIT) in Q4 2018, closing a stake of 150 shares — an estimated $5K sold.

Woodard & Company Asset Management Group first reported a position in EDIT in Q4 2017 and held it in 4 quarters. The position peaked at $5.38K in Q2 2018. 194 funds tracked by Wall St. Rank hold EDIT as of Q4 2018.

  • Woodard & Company Asset Management Group reported no remaining Editas Medicine position as of Q4 2018 after selling out during the quarter.
  • Woodard & Company Asset Management Group sold 150 Editas Medicine shares in Q4 2018, an estimated $5K.
  • Woodard & Company Asset Management Group first reported a position in Editas Medicine in Q4 2017 and held it in 4 quarters.
  • Woodard & Company Asset Management Group's Editas Medicine position peaked at $5.38K in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2018.

Based on Woodard & Company Asset Management Group's 13F filing for Q4 2018, filed 1 Feb 2019.